Plasma aminothiol oxidation in chronic hemodialysis patients

被引:79
作者
Himmelfarb, J
McMenamin, E
McMonagle, E
机构
[1] Maine Med Ctr, Div Nephrol & Renal Transplantat, Portland, ME 04102 USA
[2] Maine Med Ctr, Res Inst, Portland, ME 04102 USA
关键词
uremia; end-stage renal disease; oxidant stress; homocysteine; cysteine; glutathione; extracellular redox system; uremic toxin;
D O I
10.1046/j.1523-1755.2002.00151.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Plasma aminothiols, including homocysteine, cysteine, and glutathione, function as an important extracellular redox system. We examined the plasma aminothiol concentration and redox status in ten chronic hemodialysis patients compared to ten age-matched healthy subjects. Methods. Plasma levels of reduced, free oxidized, and protein-bound homocysteine, cysteine, cysteinylglycine, and glutathione were determined using high-pressure liquid chromatography (HPLC). Results. Total plasma homocysteine, cysteine, and cysteinylglycine levels were significantly elevated in hemodialysis patients before dialysis compared to healthy subjects. Total plasma concentration of cysteine and homocysteine significantly decreased after hemodialysis. The ratio of free oxidized to free reduced homocysteine, cysteine, cysteinylglycine, and glutathione were each significantly elevated before dialysis compared to healthy subjects, and decreased significantly by the end of dialysis. The free oxidized to reduced ratio of cysteine and homocysteine were also significantly correlated with total plasma concentrations. Conclusions. Plasma aminothiols are excessively oxidized in uremia, while the hemodialysis procedure is restorative of redox status. Oxidized aminothiols are candidate uremic toxins.
引用
收藏
页码:705 / 716
页数:12
相关论文
共 61 条
[1]  
Andersson A, 1999, CLIN CHEM, V45, P1084
[2]   Role of oxidative stress in diabetic complications - A new perspective on an old paradigm [J].
Baynes, JW ;
Thorpe, SR .
DIABETES, 1999, 48 (01) :1-9
[3]  
Becker BN, 1997, J AM SOC NEPHROL, V8, P475
[4]   Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis [J].
Boaz, M ;
Matas, Z ;
Biro, A ;
Katzir, Z ;
Green, M ;
Fainaru, M ;
Smetana, S .
KIDNEY INTERNATIONAL, 1999, 56 (03) :1078-1083
[5]  
Boaz M, 2001, CLIN NEPHROL, V55, P93
[6]   Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study [J].
Bostom, AG ;
Shemin, D ;
Lapane, KL ;
Sutherland, P ;
Nadeau, MR ;
Wilson, PWF ;
Yoburn, D ;
Bausserman, L ;
Tofler, G ;
Jacques, PF ;
Selhub, J ;
Rosenberg, IH .
ATHEROSCLEROSIS, 1996, 125 (01) :91-101
[7]   Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients - A prospective study [J].
Bostom, AG ;
Shemin, D ;
Verhoef, P ;
Nadeau, MR ;
Jacques, PF ;
Selhub, J ;
Dworkin, L ;
Rosenberg, IH .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) :2554-2558
[8]   Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes [J].
Bostom, AG ;
Lathrop, L .
KIDNEY INTERNATIONAL, 1997, 52 (01) :10-20
[9]   A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES [J].
BOUSHEY, CJ ;
BERESFORD, SAA ;
OMENN, GS ;
MOTULSKY, AG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (13) :1049-1057
[10]   Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure [J].
CeballosPicot, I ;
WitkoSarsat, V ;
MeradBoudia, M ;
Nguyen, AT ;
Thevenin, M ;
Jaudon, MC ;
Zingraff, J ;
Verger, C ;
Jungers, P ;
DescampsLatscha, B .
FREE RADICAL BIOLOGY AND MEDICINE, 1996, 21 (06) :845-853